Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Genetics

Background:

• Mixed hyperlipidemia elevates atherosclerotic cardiovascular disease risk due to high non-high-density lipoprotein (HDL) cholesterol.
• Triglyceride-rich lipoprotein metabolism is regulated by apolipoprotein C3 (APOC3), which inhibits lipoprotein lipase.

Purpose of the Study:

• To evaluate the safety and efficacy of plozasiran, an APOC3-targeting small interfering RNA, in patients with mixed hyperlipidemia.
• To assess the impact of plozasiran on fasting triglyceride levels over 48 weeks.

Main Methods:

• A 48-week, phase 2b, double-blind, randomized, placebo-controlled trial was conducted.
• Participants received subcutaneous plozasiran (10-50 mg) or placebo quarterly or half-yearly.
• The primary endpoint was the percent change in fasting triglyceride level at 24 weeks.

Main Results:

• Plozasiran demonstrated significant reductions in fasting triglyceride levels at 24 weeks across all tested doses and regimens compared to placebo.
• Reductions ranged from -44.2 to -62.4 percentage points (P<0.001).
• Worsening glycemic control was observed in 7-21% of plozasiran recipients versus 10% of placebo recipients.

Conclusions:

• Plozasiran significantly reduced triglyceride levels in patients with mixed hyperlipidemia.
• Further clinical outcomes trials are warranted to confirm the long-term efficacy and safety of plozasiran.